Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

A Curated Resource for Phosphosite-specific Signature Analysis.

Krug K, Mertins P, Zhang B, Hornbeck P, Raju R, Ahmad R, Szucs M, Mundt F, Forestier D, Jane-Valbuena J, Keshishian H, Gillette MA, Tamayo P, Mesirov JP, Jaffe JD, Carr SA, Mani DR.

Mol Cell Proteomics. 2019 Mar;18(3):576-593. doi: 10.1074/mcp.TIR118.000943. Epub 2018 Dec 18.

PMID:
30563849
2.

Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups.

Archer TC, Ehrenberger T, Mundt F, Gold MP, Krug K, Mah CK, Mahoney EL, Daniel CJ, LeNail A, Ramamoorthy D, Mertins P, Mani DR, Zhang H, Gillette MA, Clauser K, Noble M, Tang LC, Pierre-François J, Silterra J, Jensen J, Tamayo P, Korshunov A, Pfister SM, Kool M, Northcott PA, Sears RC, Lipton JO, Carr SA, Mesirov JP, Pomeroy SL, Fraenkel E.

Cancer Cell. 2018 Sep 10;34(3):396-410.e8. doi: 10.1016/j.ccell.2018.08.004.

PMID:
30205044
3.

Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography-mass spectrometry.

Mertins P, Tang LC, Krug K, Clark DJ, Gritsenko MA, Chen L, Clauser KR, Clauss TR, Shah P, Gillette MA, Petyuk VA, Thomas SN, Mani DR, Mundt F, Moore RJ, Hu Y, Zhao R, Schnaubelt M, Keshishian H, Monroe ME, Zhang Z, Udeshi ND, Mani D, Davies SR, Townsend RR, Chan DW, Smith RD, Zhang H, Liu T, Carr SA.

Nat Protoc. 2018 Jul;13(7):1632-1661. doi: 10.1038/s41596-018-0006-9.

4.

Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers.

Mundt F, Rajput S, Li S, Ruggles KV, Mooradian AD, Mertins P, Gillette MA, Krug K, Guo Z, Hoog J, Erdmann-Gilmore P, Primeau T, Huang S, Edwards DP, Wang X, Wang X, Kawaler E, Mani DR, Clauser KR, Gao F, Luo J, Davies SR, Johnson GL, Huang KL, Yoon CJ, Ding L, Fenyö D, Ellis MJ, Townsend RR, Held JM, Carr SA, Ma CX.

Cancer Res. 2018 May 15;78(10):2732-2746. doi: 10.1158/0008-5472.CAN-17-1990. Epub 2018 Feb 22.

5.

Time to Neurological Deterioration in Ischemic Stroke.

Siegler JE, Albright KC, George AJ, Boehme AK, Gillette MA, Kumar AD, Aswani M, Martin-Schild S.

Med Student Res J. 2017 Winter;4:18-24. doi: 10.15404/msrj/03.2016.0005.

6.

Quantitative, multiplexed workflow for deep analysis of human blood plasma and biomarker discovery by mass spectrometry.

Keshishian H, Burgess MW, Specht H, Wallace L, Clauser KR, Gillette MA, Carr SA.

Nat Protoc. 2017 Aug;12(8):1683-1701. doi: 10.1038/nprot.2017.054. Epub 2017 Jul 27.

7.

Corrigendum: Proteogenomic integration reveals therapeutic targets in breast cancer xenografts.

Huang KL, Li S, Mertins P, Cao S, Gunawardena HP, Ruggles KV, Mani DR, Clauser KR, Tanioka M, Usary J, Kavuri SM, Xie L, Yoon C, Qiao JW, Wrobel J, Wyczalkowski MA, Erdmann-Gilmore P, Snider JE, Hoog J, Singh P, Niu B, Guo Z, Sun SQ, Sanati S, Kawaler E, Wang X, Scott A, Ye K, McLellan MD, Wendl MC, Malovannaya A, Held JM, Gillette MA, Fenyö D, Kinsinger CR, Mesri M, Rodriguez H, Davies SR, Perou CM, Ma C, Townsend RR, Chen X, Carr SA, Ellis MJ, Ding L.

Nat Commun. 2017 Apr 25;8:15479. doi: 10.1038/ncomms15479. No abstract available.

8.

Proteogenomic integration reveals therapeutic targets in breast cancer xenografts.

Huang KL, Li S, Mertins P, Cao S, Gunawardena HP, Ruggles KV, Mani DR, Clauser KR, Tanioka M, Usary J, Kavuri SM, Xie L, Yoon C, Qiao JW, Wrobel J, Wyczalkowski MA, Erdmann-Gilmore P, Snider JE, Hoog J, Singh P, Niu B, Guo Z, Sun SQ, Sanati S, Kawaler E, Wang X, Scott A, Ye K, McLellan MD, Wendl MC, Malovannaya A, Held JM, Gillette MA, Fenyö D, Kinsinger CR, Mesri M, Rodriguez H, Davies SR, Perou CM, Ma C, Reid Townsend R, Chen X, Carr SA, Ellis MJ, Ding L.

Nat Commun. 2017 Mar 28;8:14864. doi: 10.1038/ncomms14864.

9.

Transcriptional Categorization of the Etiology of Pneumonia Syndrome in Pediatric Patients in Malaria-Endemic Areas.

Silterra J, Gillette MA, Lanaspa M, Pellé KG, Valim C, Ahmad R, Acácio S, Almendinger KD, Tan Y, Madrid L, Alonso PL, Carr SA, Wiegand RC, Bassat Q, Mesirov JP, Milner DA Jr, Wirth DF.

J Infect Dis. 2017 Jan 15;215(2):312-320. doi: 10.1093/infdis/jiw531.

10.

Proteogenomics connects somatic mutations to signalling in breast cancer.

Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, Wang X, Qiao JW, Cao S, Petralia F, Kawaler E, Mundt F, Krug K, Tu Z, Lei JT, Gatza ML, Wilkerson M, Perou CM, Yellapantula V, Huang KL, Lin C, McLellan MD, Yan P, Davies SR, Townsend RR, Skates SJ, Wang J, Zhang B, Kinsinger CR, Mesri M, Rodriguez H, Ding L, Paulovich AG, Fenyö D, Ellis MJ, Carr SA; NCI CPTAC.

Nature. 2016 Jun 2;534(7605):55-62. doi: 10.1038/nature18003. Epub 2016 May 25.

11.

Unfractionated heparin anticoagulation using estimated blood volume based dosing versus weight-based dosing in a Veteran population.

Gillette MA, Franck A, Reeder DN, Knott A, Frohnapple DJ.

Am J Health Syst Pharm. 2015 Dec 1;72(23 Suppl 3):S171-6. doi: 10.2146/sp150027.

PMID:
26582305
12.

Responses to Bacteria, Virus, and Malaria Distinguish the Etiology of Pediatric Clinical Pneumonia.

Valim C, Ahmad R, Lanaspa M, Tan Y, Acácio S, Gillette MA, Almendinger KD, Milner DA Jr, Madrid L, Pellé K, Harezlak J, Silterra J, Alonso PL, Carr SA, Mesirov JP, Wirth DF, Wiegand RC, Bassat Q.

Am J Respir Crit Care Med. 2016 Feb 15;193(4):448-59. doi: 10.1164/rccm.201506-1100OC.

13.

Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria.

Virani SS, Akeroyd JM, Nambi V, Maddox TM, Gillette MA, Michael Ho P, Rumsfeld J, Petersen LA, Ballantyne CM.

Am J Med. 2015 Nov;128(11):1253-6. doi: 10.1016/j.amjmed.2015.05.027. Epub 2015 Jun 10.

PMID:
26071828
14.

Multiplexed, Quantitative Workflow for Sensitive Biomarker Discovery in Plasma Yields Novel Candidates for Early Myocardial Injury.

Keshishian H, Burgess MW, Gillette MA, Mertins P, Clauser KR, Mani DR, Kuhn EW, Farrell LA, Gerszten RE, Carr SA.

Mol Cell Proteomics. 2015 Sep;14(9):2375-93. doi: 10.1074/mcp.M114.046813. Epub 2015 Feb 27.

15.

Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV - an alternative viewpoint.

Gillette MA, Shah BM, Schafer JJ, DeSimone JA Jr.

Pharmacotherapy. 2014 Sep;34(9):e173-4. doi: 10.1002/phar.1478. No abstract available.

PMID:
25182330
16.

Persistent leukocytosis-is this a persistent problem for patients with acute ischemic stroke?

Boehme AK, Kumar AD, Lyerly MJ, Gillette MA, Siegler JE, Albright KC, Beasley TM, Martin-Schild S.

J Stroke Cerebrovasc Dis. 2014 Aug;23(7):1939-43. doi: 10.1016/j.jstrokecerebrovasdis.2014.02.004. Epub 2014 Apr 29.

17.

Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels.

Mertins P, Yang F, Liu T, Mani DR, Petyuk VA, Gillette MA, Clauser KR, Qiao JW, Gritsenko MA, Moore RJ, Levine DA, Townsend R, Erdmann-Gilmore P, Snider JE, Davies SR, Ruggles KV, Fenyo D, Kitchens RT, Li S, Olvera N, Dao F, Rodriguez H, Chan DW, Liebler D, White F, Rodland KD, Mills GB, Smith RD, Paulovich AG, Ellis M, Carr SA.

Mol Cell Proteomics. 2014 Jul;13(7):1690-704. doi: 10.1074/mcp.M113.036392. Epub 2014 Apr 9.

18.

Simplified and efficient quantification of low-abundance proteins at very high multiplex via targeted mass spectrometry.

Burgess MW, Keshishian H, Mani DR, Gillette MA, Carr SA.

Mol Cell Proteomics. 2014 Apr;13(4):1137-49. doi: 10.1074/mcp.M113.034660. Epub 2014 Feb 11.

19.

Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies.

Skates SJ, Gillette MA, LaBaer J, Carr SA, Anderson L, Liebler DC, Ransohoff D, Rifai N, Kondratovich M, Težak Ž, Mansfield E, Oberg AL, Wright I, Barnes G, Gail M, Mesri M, Kinsinger CR, Rodriguez H, Boja ES.

J Proteome Res. 2013 Dec 6;12(12):5383-94. doi: 10.1021/pr400132j. Epub 2013 Oct 28.

20.

Integrated proteomic analysis of post-translational modifications by serial enrichment.

Mertins P, Qiao JW, Patel J, Udeshi ND, Clauser KR, Mani DR, Burgess MW, Gillette MA, Jaffe JD, Carr SA.

Nat Methods. 2013 Jul;10(7):634-7. doi: 10.1038/nmeth.2518. Epub 2013 Jun 9.

21.

Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry.

Gillette MA, Carr SA.

Nat Methods. 2013 Jan;10(1):28-34. doi: 10.1038/nmeth.2309.

22.

Identification of modifiable and nonmodifiable risk factors for neurologic deterioration after acute ischemic stroke.

Siegler JE, Boehme AK, Kumar AD, Gillette MA, Albright KC, Beasley TM, Martin-Schild S.

J Stroke Cerebrovasc Dis. 2013 Oct;22(7):e207-13. doi: 10.1016/j.jstrokecerebrovasdis.2012.11.006. Epub 2012 Dec 16.

23.

What change in the National Institutes of Health Stroke Scale should define neurologic deterioration in acute ischemic stroke?

Siegler JE, Boehme AK, Kumar AD, Gillette MA, Albright KC, Martin-Schild S.

J Stroke Cerebrovasc Dis. 2013 Jul;22(5):675-82. doi: 10.1016/j.jstrokecerebrovasdis.2012.04.012. Epub 2012 Jun 21.

24.

Clinical experience with ranolazine in a veteran population with chronic stable angina.

Reeder DN, Gillette MA, Franck AJ, Frohnapple DJ.

Ann Pharmacother. 2012 Jan;46(1):42-50. doi: 10.1345/aph.1Q487. Epub 2012 Jan 3.

PMID:
22215689
25.

A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease.

Addona TA, Shi X, Keshishian H, Mani DR, Burgess M, Gillette MA, Clauser KR, Shen D, Lewis GD, Farrell LA, Fifer MA, Sabatine MS, Gerszten RE, Carr SA.

Nat Biotechnol. 2011 Jun 19;29(7):635-43. doi: 10.1038/nbt.1899.

26.

Accurate inclusion mass screening: a bridge from unbiased discovery to targeted assay development for biomarker verification.

Jaffe JD, Keshishian H, Chang B, Addona TA, Gillette MA, Carr SA.

Mol Cell Proteomics. 2008 Oct;7(10):1952-62. doi: 10.1074/mcp.M800218-MCP200. Epub 2008 Jun 4.

27.

Metagene projection for cross-platform, cross-species characterization of global transcriptional states.

Tamayo P, Scanfeld D, Ebert BL, Gillette MA, Roberts CW, Mesirov JP.

Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5959-64. Epub 2007 Mar 27.

28.

Protein biomarker discovery and validation: the long and uncertain path to clinical utility.

Rifai N, Gillette MA, Carr SA.

Nat Biotechnol. 2006 Aug;24(8):971-83. Review.

PMID:
16900146
29.

PEPPeR, a platform for experimental proteomic pattern recognition.

Jaffe JD, Mani DR, Leptos KC, Church GM, Gillette MA, Carr SA.

Mol Cell Proteomics. 2006 Oct;5(10):1927-41. Epub 2006 Jul 19. Erratum in: Mol Cell Proteomics. 2009 Mar;8(3):584.

30.

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP.

Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. Epub 2005 Sep 30.

31.

Place of pattern in proteomic biomarker discovery.

Gillette MA, Mani DR, Carr SA.

J Proteome Res. 2005 Jul-Aug;4(4):1143-54. Review.

PMID:
16083265
32.
33.

Tracheal gas insufflation and related techniques to introduce gas flow into the trachea.

Hess DR, Gillette MA.

Respir Care. 2001 Feb;46(2):119-29. Review.

PMID:
11175241
34.

Protein kinase modulation of GABAA currents in rabbit retinal rod bipolar cells.

Gillette MA, Dacheux RF.

J Neurophysiol. 1996 Nov;76(5):3070-86.

PMID:
8930256
35.

GABA- and glycine-activated currents in the rod bipolar cell of the rabbit retina.

Gillette MA, Dacheux RF.

J Neurophysiol. 1995 Aug;74(2):856-75.

PMID:
7472389

Supplemental Content

Loading ...
Support Center